In vitro models have shown that the overexpression/amplification of BRF2 and DSN1, along with the HER2 I767M mutation, compensate for the lack of HER2 amplification in the HER2-negative components of these breast carcinomas [90]. This evidence concerns the gene ERBB2 and breast carcinoma.